Kwality Pharmaceuticals FY26 Revenue Up 36% to ₹503 Crore

Kwality Pharmaceuticals reported audited FY26 results with revenue of ₹503 crore, up 36% YoY, and PAT of ₹67.35 crore, up 69% YoY.
EBITDA margins expanded 200 bps to 24% driven by improved product mix and operating leverage benefits.
The company achieved its highest-ever quarterly revenue of ₹157.11 crore in Q4 FY26 and received an ICRA credit rating upgrade to BBB+.
Management provided FY27 guidance of ₹650 crore revenue and ₹100 crore PAT, targeting ₹1,000 crore revenue by FY29.